STA
MRSN

Summit Trail Advisors’s Mersana Therapeutics MRSN Stock Holding History

Summit Trail Advisors’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-2
Closed -$1K – 1204
2017
Q4 		$1K Buy
+2
New +$872 ﹤0.01% 1827

Other funds holding MRSN

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
PAI
ProQuest Associates IV Naples, Florida $53M AUM 3.35% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCP
Rho Capital Partners New York $20.4M AUM
Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Summit Trail Advisors's MRSN Position: Q1 2018 in Review

Summit Trail Advisors sold out of Mersana Therapeutics (MRSN) in Q1 2018, closing a stake of 2 shares — an estimated $1K sold.

Summit Trail Advisors first reported a position in MRSN in Q4 2017 and held it in 1 quarter. The position peaked at $1K in Q4 2017. 56 funds tracked by Wall St. Rank hold MRSN as of Q1 2018.

  • Summit Trail Advisors reported no remaining Mersana Therapeutics position as of Q1 2018 after selling out during the quarter.
  • Summit Trail Advisors sold 2 Mersana Therapeutics shares in Q1 2018, an estimated $1K.
  • Summit Trail Advisors first reported a position in Mersana Therapeutics in Q4 2017 and held it in 1 quarter.
  • Summit Trail Advisors's Mersana Therapeutics position peaked at $1K in Q4 2017.
  • 56 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q1 2018.

Based on Summit Trail Advisors's 13F filing for Q1 2018, filed 21 May 2018.